Decoy Therapeutics (DCOY) Net Cash Flow (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Net Cash Flow of -$2.9 million for Q1 2026, down 354.19% year-over-year from $1.1 million in Q1 2025, and down 148.97% quarter-over-quarter from $5.9 million in Q4 2025.
Decoy Therapeutics (DCOY) Net Cash Flow (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Net Cash Flow for 12 consecutive years, with -$2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 354.19% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at $6.2 million (up 341.66% YoY), while the FY2025 annual figure was $8.3 million, up 338.8% from the prior year.
- Net Cash Flow slipped to -$2.9 million in Q1 2026 per DCOY's latest filing, from $5.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $5.9 million in Q4 2025 and bottomed at -$5.8 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$1.2 million across 5 years, with a median of -$1.5 million in 2024.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 395.62% — and 2025, when it surged 37511.94%.
- Decoy Therapeutics' Net Cash Flow stood at -$4.7 million in 2022, then surged by 64.35% to -$1.7 million in 2023, then soared by 49.45% to -$849501.0 in 2024, then soared by 794.56% to $5.9 million in 2025, then slumped by 148.97% to -$2.9 million in 2026.
- Business Quant data shows DCOY's Net Cash Flow at -$2.9 million in Q1 2026, $5.9 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Decoy Therapeutics | 1.82 Mn | 1.82 Mn | - | 510,924.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 510,924.00 |
| Jun 30, 2026 | 510,924.00 |
| Mar 31, 2026 | -2.89 Mn |
| Mar 31, 2026 | -2.89 Mn |
| Dec 31, 2025 | 5.90 Mn |
| Dec 31, 2025 | 5.90 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | -636,148.00 |
| Mar 31, 2025 | -636,148.00 |
| Dec 31, 2024 | -849,501.00 |
| Dec 31, 2024 | -849,501.00 |
| Sep 30, 2024 | 11,206.00 |
| Sep 30, 2024 | 11,206.00 |
| Jun 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.53 Mn |
| Mar 31, 2024 | -1.53 Mn |